JPM 2022: Post-conference digital health roundup

Digital health was front and center at the annual JP Morgan Conference this month, with medtech majors investing heavily in the sector, plus, explorations of barriers to adopting AI in quality assurance, risk-sharing in telehealth, and at least one well-known health system looking to invest in digital health.

Here are some highlights:

For our part, a highlight of the conference was another installation of our Digital Health C-Suite Series with our friends at HealthXL, called “The Holy Grail of Digital Health: Scaling Patient and Clinician Adoption.”

Our session’s presenters – Lilly Biomedicines’ Head of Digital Health Kirk Keaffaber; Ritesh Patel, senior partner for global digital health at FINN Partners; and Chandana Fitzgerald, HealthXL’s GM & chief medical officer – offered valuable insights and lessons from their digital adoption experience. Here are a few key takeaways from our discussion of the challenges facing life science companies that are adopting digital:

Finally, we announced during the conference a partnership with Sanofi to bring to market a next-generation digital companion app for one of Sanofi’s most important treatments. The BrightInsight® Platform will serve as the underlying infrastructure to accelerate continuous development of one of Sanofi’s best-in-class Software as a Medical Device (SaMD) solutions.

Leveraging our BrightInsight Platform, the new app will support patients from therapy onboarding to chronic disease management via a patient mobile app that integrates with third-party systems in a connected ecosystem. Users will be able to manage their complex conditions with custom profiles and content, and step-by-step therapy administration guidance.

Thank you to everyone who shared our news about Sanofi and to those who attended our virtual Digital Health C-Suite Series discussion. We hope to see you all in person at JPM 2023!

Back to Blog